Safi U Khan1, Muhammad Zia Khan1, Muhammad Shahzeb Khan2, Ahmed Mahmood3, Ankur Kalra4, Edo Kaluski5, Erin D Michos6, Mohamad Alkhouli7. 1. Department of Medicine, West Virginia University, 1 Medical Center Drive, Morgantown, WV 26508, USA. 2. Department of Medicine, John H Stroger Jr. Hospital of Cook County, 1969 Ogden Ave, Chicago, IL 60612, USA. 3. Department of Internal Medicine, Eastern Idaho Regional Medical Center, 3100 Channing Way, Idaho Falls, ID 83404, USA. 4. Department of Cardiovascular Medicine, Heart and Vascular Institute, Cleveland Clinic, 9500 Euclid Ave, Cleveland, OH 44195, USA. 5. Department of Cardiovascular Medicine, Guthrie Health System/Robert Packer Hospital, 1 Guthrie Square, Sayre, PA 18840, USA. 6. Division of Cardiology, Department of Medicine, Ciccarone Center for the Prevention of Cardiovascular Disease, Johns Hopkins School of Medicine, Blalock 524-B, 600 North Wolfe Street, Baltimore, MD 21287, USA. 7. Department of Cardiovascular Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA.
Abstract
AIMS: To compare early de-escalation of dual antiplatelet therapy (DAPT) (1-3 months) to monotherapy with either P2Y12 inhibitor or aspirin vs. 12 months DAPT after percutaneous coronary intervention (PCI) with drug-eluting stent (DES). METHODS AND RESULTS: Electronic databases of Medline, Embase, and Cochrane library were searched through February 2020 to identify randomized controlled trials. A Bayesian network meta-analysis was conducted with random effects model. The main endpoints of interest were cardiovascular mortality and total bleeding events. Among seven trials (35 821 patients), 52.6% patients were presented with acute coronary syndrome. A total of 3359 patients and 14 530 patients were de-escalated to aspirin and P2Y12 inhibitor monotherapy, respectively. At a median follow-up of 12 months, compared with 12 months of DAPT, there was no significant difference in cardiovascular mortality between 1-month DAPT followed by P2Y12 inhibitor monotherapy [hazard ratio (HR) 0.84 (95% credible interval 0.29-2.43)], 3 months of DAPT followed by P2Y12 inhibitor monotherapy [HR 0.74 (0.39-1.46)], or 3 months of DAPT [HR 1.00 (0.54-1.86)] followed by aspirin monotherapy. Except for de-escalation of DAPT to aspirin monotherapy after 3 months [HR 0.75 (0.43-1.20)], de-escalation to P2Y12 inhibitor monotherapy after 1 month [HR 0.28 (0.10-0.83)], or 3 months [HR 0.57 (0.33-0.98)] were associated with significant decrease in total bleeding events. There were no significant differences in terms of ischaemic endpoints among different DAPT strategies. CONCLUSION: Early de-escalation of DAPT (1-3 months) to monotherapy with a P2Y12 inhibitor instead of aspirin might be a safer and equally effective approach compared with 12 months of DAPT in patients with PCI and DES. Published on behalf of the European Society of Cardiology. All rights reserved.
AIMS: To compare early de-escalation of dual antiplatelet therapy (DAPT) (1-3 months) to monotherapy with either P2Y12 inhibitor or aspirin vs. 12 months DAPT after percutaneous coronary intervention (PCI) with drug-eluting stent (DES). METHODS AND RESULTS: Electronic databases of Medline, Embase, and Cochrane library were searched through February 2020 to identify randomized controlled trials. A Bayesian network meta-analysis was conducted with random effects model. The main endpoints of interest were cardiovascular mortality and total bleeding events. Among seven trials (35 821 patients), 52.6% patients were presented with acute coronary syndrome. A total of 3359 patients and 14 530 patients were de-escalated to aspirin and P2Y12 inhibitor monotherapy, respectively. At a median follow-up of 12 months, compared with 12 months of DAPT, there was no significant difference in cardiovascular mortality between 1-month DAPT followed by P2Y12 inhibitor monotherapy [hazard ratio (HR) 0.84 (95% credible interval 0.29-2.43)], 3 months of DAPT followed by P2Y12 inhibitor monotherapy [HR 0.74 (0.39-1.46)], or 3 months of DAPT [HR 1.00 (0.54-1.86)] followed by aspirin monotherapy. Except for de-escalation of DAPT to aspirin monotherapy after 3 months [HR 0.75 (0.43-1.20)], de-escalation to P2Y12 inhibitor monotherapy after 1 month [HR 0.28 (0.10-0.83)], or 3 months [HR 0.57 (0.33-0.98)] were associated with significant decrease in total bleeding events. There were no significant differences in terms of ischaemic endpoints among different DAPT strategies. CONCLUSION: Early de-escalation of DAPT (1-3 months) to monotherapy with a P2Y12 inhibitor instead of aspirin might be a safer and equally effective approach compared with 12 months of DAPT in patients with PCI and DES. Published on behalf of the European Society of Cardiology. All rights reserved.
Authors: Fausto Feres; Ricardo A Costa; Alexandre Abizaid; Martin B Leon; J Antônio Marin-Neto; Roberto V Botelho; Spencer B King; Manuela Negoita; Minglei Liu; J Eduardo T de Paula; José A Mangione; George X Meireles; Hélio J Castello; Eduardo L Nicolela; Marco A Perin; Fernando S Devito; André Labrunie; Décio Salvadori; Marcos Gusmão; Rodolfo Staico; J Ribamar Costa; Juliana P de Castro; Andrea S Abizaid; Deepak L Bhatt Journal: JAMA Date: 2013-12-18 Impact factor: 56.272
Authors: Giuseppe De Luca; Sander A Damen; Cyril Camaro; Edouard Benit; Monica Verdoia; Saman Rasoul; Houng Bang Liew; Jawed Polad; Wan A Ahmad; Robaayah Zambahari; Sonja Postma; Elvin Kedhi; Harry Suryapranata Journal: EuroIntervention Date: 2019-12-06 Impact factor: 6.534
Authors: Safi U Khan; Muhammad U Khan; Hammad Rahman; Muhammad Shahzeb Khan; Haris Riaz; Matthew Novak; Isaac Opoku-Asare; Edo Kaluski Journal: Cardiovasc Revasc Med Date: 2018-06-12
Authors: Glenn N Levine; Eric R Bates; John A Bittl; Ralph G Brindis; Stephan D Fihn; Lee A Fleisher; Christopher B Granger; Richard A Lange; Michael J Mack; Laura Mauri; Roxana Mehran; Debabrata Mukherjee; L Kristin Newby; Patrick T O'Gara; Marc S Sabatine; Peter K Smith; Sidney C Smith Journal: Circulation Date: 2016-03-29 Impact factor: 29.690
Authors: Alessandro Liberati; Douglas G Altman; Jennifer Tetzlaff; Cynthia Mulrow; Peter C Gøtzsche; John P A Ioannidis; Mike Clarke; P J Devereaux; Jos Kleijnen; David Moher Journal: BMJ Date: 2009-07-21
Authors: W K Hass; J D Easton; H P Adams; W Pryse-Phillips; B A Molony; S Anderson; B Kamm Journal: N Engl J Med Date: 1989-08-24 Impact factor: 91.245
Authors: Pascal Vranckx; Marco Valgimigli; Peter Jüni; Christian Hamm; Philippe Gabriel Steg; Dik Heg; Gerrit Anne van Es; Eugene P McFadden; Yoshinobu Onuma; Cokky van Meijeren; Ply Chichareon; Edouard Benit; Helge Möllmann; Luc Janssens; Maurizio Ferrario; Aris Moschovitis; Aleksander Zurakowski; Marcello Dominici; Robert Jan Van Geuns; Kurt Huber; Ton Slagboom; Patrick W Serruys; Stephan Windecker Journal: Lancet Date: 2018-08-27 Impact factor: 79.321
Authors: Jacek Kubica; Piotr Adamski; Piotr Niezgoda; Aldona Kubica; Przemysław Podhajski; Malwina Barańska; Julia M Umińska; Łukasz Pietrzykowski; Małgorzata Ostrowska; Jolanta M Siller-Matula; Jolita Badarienė; Stanisław Bartuś; Andrzej Budaj; Sławomir Dobrzycki; Łukasz Fidor; Mariusz Gąsior; Jacek Gessek; Marek Gierlotka; Robert Gil; Jarosław Gorący; Paweł Grzelakowski; Tomasz Hajdukiewicz; Miłosz Jaguszewski; Marianna Janion; Jarosław Kasprzak; Adam Kern; Artur Klecha; Andrzej Kleinrok; Wacław Kochman; Bartosz Krakowiak; Jacek Legutko; Maciej Lesiak; Marcin Nosal; Grzegorz Piotrowski; Andrzej Przybylski; Tomasz Roleder; Grzegorz Skonieczny; Grzegorz Sobieszek; Agnieszka Tycińska; Dariusz Wojciechowski; Wojciech Wojakowski; Jarosław Wójcik; Marzenna Zielińska; Aleksander Żurakowski; Giuseppe Specchia; Diana A Gorog; Eliano P Navarese Journal: Cardiol J Date: 2021-06-07 Impact factor: 2.737